title: Interleukin-1 beta expression and treatment outcome in acute myelogenous leukemia.
authors.forename: H D
authors.initials: HD
authors.lastname: Preisler
authors.forename: A
authors.initials: A
authors.lastname: Raza
authors.forename: C
authors.initials: C
authors.lastname: Kukla
authors.forename: R
authors.initials: R
authors.lastname: Larson
authors.forename: J
authors.initials: J
authors.lastname: Goldberg
authors.forename: G
authors.initials: G
authors.lastname: Browman
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015152:Blotting, Northern; D001853:Bone Marrow / Q000473:pathology; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use*; D003630:Daunorubicin / Q000008:administration & dosage; D015870:Gene Expression; D006801:Humans; D007375:Interleukin-1 / Q000235:genetics*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D011379:Prognosis; D012074:Remission Induction; D014158:Transcription, Genetic
chemical_list: D007375:Interleukin-1; D003561:Cytarabine; D003630:Daunorubicin